HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 10, 2003
- Eisai's Overseas Sales to Rise to 53% of Total in FY2006: President Naito
March 10, 2003
- Novartis Refocusing Marketing Efforts on Zaditen
March 10, 2003
- WORLD NEWS IN BRIEF
March 10, 2003
- Sales of JCROA Members Up 61% to \39 Bil. in 2002
March 10, 2003
- TOPICS 2 articles
March 10, 2003
- Biogen Japan Preparing for Clinical Trial of AMEVIVE
March 10, 2003
- 6-year Education to Be Key Issue for JPA in FY2003
March 10, 2003
- Japanese Drug Makers Are Innovative But Regulations Are a Problem: Prof.Kneller at JPLA Seminar
March 10, 2003
- Detailed Rules for CRC Certification Announced by JSCPT
March 10, 2003
- PHARMA NETWORK Codevelops MR Evaluation System
March 10, 2003
- Korosho to Use Electronized Data to Optimize Nursing Care Benefits
March 10, 2003
- BUSINESS NEWS IN BRIEF
March 10, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 10, 2003
- WEBSITE NEWS
March 10, 2003
- Fujisawa Updates R&D Pipeline
March 10, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
March 10, 2003
- PRESS SEMINAR
March 10, 2003
- Gov't Allows Private Companies to Operate Medical Institutions
March 10, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 10, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
